Our People

Jeppe is the CEO of NBCD, as well as the Group CEO of Sanos (the parent company of NBCD, Neuroscios, Blueskin and Sanos Clinic).

Jeppe holds a master’s in Pharmaceutical Science (M.Sc. Pharm) from University of Copenhagen, Denmark, and joined Nordic Bioscience in 2007 as a CRA. In 2010 he became Head of Clinical Development in 2010, and in 2014 he transitioned into his position as the CEO of NBCD.

Jeppe has been involved on an operational and executive level in numerous clinical studies with more than 18,000 patients within various therapeutic fields but primarily within osteoporosis and osteoarthritis leading to market approved drugs in both indications. Jeppe has been spearheading the journey of building Sanos from a handful of people back in 2006 to the 250 employees’ midsize multi-niche CRO company of 2025.

With his history of success in building and growing organizations, his strong expertise from both CRO and Investigator perspective, and his in-depth project leadership in clinical development, he has an ability to identify market trends and conceptualize strategies with an aim of innovation to improve work and business processes.

Anne is Director, Clinical Operations in NBCD and has been with the company since 2012. She holds a master’s in Medicine with Industrial Specialization, Translational Medicine (Cand.Scient.Med) from University of Aalborg, Denmark, and started her career in clinical research in 2011.

Anne has had various responsibilities within Study Operations through the years and is now in charge of the Clinical Trial- and Document Systems Management groups. She is passionate about the facilitation and management of clinical trials and have been involved in several clinical studies throughout the years gaining experience within osteoarthritis, osteoporosis and rheumatoid arthritis.

Anne played an integral role in the development NBCDs Risk-Based Monitoring Approach, and she has a curios approach to all new challenges. Furthermore, she was an important part of the team through the expansion of the Clinical Operations Department.

Asger is Managing Director of NBCD & Integrated Solutions in Sanos. He joined the company in 2023 as Executive Director, Project Delivery and holds a master’s in pharmaceutical science (M.Sc.Pharm) from the University of Copenhagen and a Diploma in Pharmaceutical Medicine from the University of Basel.

For 20+ years, Asger has held management positions across small to mid-size pharma and biotech, most recently as VP Clinical Operations at UNION therapeutics A/S.

Sara is the Chief Operating Officer of Sanos and has been with the company since 2011. She holds a master’s in Pharmaceutical Science (M.Sc. Pharm) from University of Copenhagen, Denmark, and started her career in NBCD as a Clinical Research Associate.

Sara has held many positions within Study Operations through the years and before shifting her focus to the management of the organization, Sara was involved in numerous clinical studies with a total of more than 18,000 patients within the therapeutic fields of osteoarthritis and osteoporosis.

Sara headed the successful expansion of the Clinical Operations Department and the integration of NBCDs Quality Management System, including implementation of Risk-Based Monitoring and various computerized systems.

Now, Sara is actively focusing on running a smooth organization with very low staff turnover, while simultaneously ensuring successful conduction of the clinical trials.

Asger is the Chief Scientific Officer of Sanos and is an internationally renowned expert in osteoarthritis (OA) drug development, OA pain, and clinical trial design. He joined NBCD in 2013, and assumed the position as Medical Director in 2014. In 2021, he transitioned into his current position as group CSO.

Asger holds a master’s in Pharmaceutical Science (M.Sc. Pharm) from University of Copenhagen, Denmark and has held several leading positions in pharma and clinical research organizations within regulatory affairs, medical affairs, and clinical science. He has published more than 30 peer-reviewed papers, primarily on OA science, in high-ranking journals, and has been cited more than 1000 times. Asger has played key roles in the design and conduct of landmark osteoarthritis trials, including the sprifermin FORWARD trial published in JAMA in 2019, and is a frequent speaker at OARSI, EULAR, and ACR conferences, where more than 50 original abstracts have been presented, in addition to invited speaker sessions on OA trial design and placebo response mitigation.

As Chief Scientific Officer, Asger currently leads the scientific affairs activities of Sanos and the subsidiary of NBCD, a Contract-Research Organization specialized in OA clinical trials. As chief scientist, Asger was the primary responsible person for the design and conduct of 3 global phase III, 15 phase II and 5 phase I trials totaling approximately 10,000 study participants evaluating experimental treatments primarily within knee osteoarthritis.

Asger is actively researching in the fields of osteoarthritis with a particular focus on optimizing clinical trial methodology and outcome.